Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 19:18:11795549241277181.
doi: 10.1177/11795549241277181. eCollection 2024.

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer

Eun-Mi Yu  1 , Ishan Patel  2 , Min Woo Hwang  3 , Faran Polani  2 , Jeanny B Aragon-Ching  1   4
Affiliations
Review

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer

Eun-Mi Yu et al. Clin Med Insights Oncol. .

Abstract

The management of metastatic hormone-sensitive prostate cancer (mHSPC) or castration-sensitive prostate cancer (mCSPC) has become increasingly complex with the tremendous progress that has been made in this space within the past few decades. In the early days of androgen deprivation therapy (ADT), ADT monotherapy was the mainstay for treatment of advanced prostate cancer. However, novel hormone therapies in the form of androgen receptor pathway inhibitors (ARPI) have emerged; vaccine therapy, chemotherapy with docetaxel and cabazitaxel, and radioactive ligands have shaped the treatment of metastatic prostate cancer in the last decade. Following the initial approval of several drugs for use in metastatic castration-resistant prostate cancer (mCRPC) in combination with primary ADT, these agents were studied and subsequently approved for use in mCSPC. Therefore, ADT monotherapy no longer constitutes an optimal therapeutic option for otherwise fit patients who present with mCSPC. We focus on the treatment of first-line de novo mHSPC or mCSPC and explore frontline doublet and triplet therapy and the pivotal trials that led to their United States Food and Drug Administration approval.

Keywords: Prostate cancer; androgen deprivation therapy; androgen receptor pathway inhibitors; chemotherapy; metastatic hormone-sensitive prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JBA-C serves in the Speakers’ Bureau of BMS and Astellas/Pfizer/Seattle Genetics and serves in the Advisory Board of Pfizer/EMD Serono, Merck and AstraZeneca and Immunomedics, Janssen, Pfizer/Astellas, Seagen, Dendreon, Bayer. E-MY, MWH, IP, and FP have no conflicts to declare.

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12-49. doi: 10.3322/caac.21820 - DOI - PubMed
    1. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol. 1994;50:267-273. doi: 10.1016/0960-0760(94)90131-7 - DOI - PubMed
    1. O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317-2325. doi: 10.1038/sj.bjc.6601879 - DOI - PMC - PubMed
    1. U.S. Food and Drug Administration. FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer. FDA. Published February 9, 2019. Accessed November 8, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro...
    1. U.S. Food and Drug Administration. FDA approves enzalutamide for metastatic castration-sensitive prostate cancer. FDA. Published December 20, 2019. Accessed November 8, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro...

LinkOut - more resources